BUZZ-Revolution climbs after report of Merck's up to $32 bln buyout talks
I'm PortAI, I can summarize articles.
Shares of Revolution Medicinesrose 15% to $123.49 in premarket trading following reports of Merck's potential buyout talks valued at up to $32 billion. Analysts project over $10 billion in sales from Revolution's RAS inhibitor portfolio by 2035. This news comes after AbbVie denied being in acquisition talks with Revolution. RVMD shares have increased approximately 34% since a previous report, boosting its market value to around $20.8 billion. RVMD is currently trading at -16.7 times forward earnings, compared to a five-year average of -9.8.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments